Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 16/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7839040 | 0.88 | FOLH1 (0.63) | FOLH1CYP1A2GRM3NAALAD2 | |
| SCHEMBL13726298 | 0.84 | FOLH1 (0.73) | FOLH1GRM3NAALAD2 | |
| SCHEMBL5054462 | 0.84 | FOLH1 (0.57) | FOLH1CYP1A2GRM3NAALAD2 | |
| SCHEMBL5059822 | 0.83 | FOLH1 (0.57) | FOLH1CYP1A2GRM3NAALAD2 | |
| SCHEMBL29027157 | 0.83 | FOLH1 (0.59) | FOLH1CYP1A2GRM3NAALAD2 | |
| SCHEMBL535764 | 0.82 | — | — | |
| SCHEMBL1752169 | 0.82 | — | — | |
| SCHEMBL1751707 | 0.82 | — | — | |
| SCHEMBL108166 | 0.82 | FOLH1 (0.76) | FOLH1GRM3NAALAD2 | |
| SCHEMBL7839968 | 0.80 | FOLH1 (0.64) | FOLH1CYP1A2GRM3NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1093453-B1 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARM INC (US) | 2005-09-28 | — | — | EP | claimed |
| EP-1571141-A2 | Naaladase inhibitors useful as pharmaceutical compounds and compositions | GUILFORD PHARMACEUTICALS INC. (US) | 2005-09-07 | — | — | EP | claimed |
| US-20050080139-A1 | Naaladase inhibitors for treating huntington's disease | GUILFORD PHARMACEUTICALS INC. | 2005-04-14 | — | — | US | claimed |
| US-6806261-B2 | CONTROL RELEASE TRANSFORMING GROWTH FACTOR; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIPROLIFERATIVE AGENT | GUILFORD PHARMACEUTICALS INC. | 2004-10-19 | — | — | US | claimed |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | GUILFORD PHARMACEUTICALS INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004078180-A2 | NAALADASE INHIBITORS FOR TREATING OPIOID TOLERANCE | GUILFORD PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | claimed |
| EP-1202717-B1 | USE OF NAALADASE INHIBITORS FOR TREATING ANXIETY AND MEMORY DISORDERS | GUILFORD PHARM INC (US) | 2004-03-03 | — | — | EP | claimed |
| EP-1140048-B1 | USE OF NAALADASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CERTAIN DISEASES | GUILFORD PHARM INC (US) | 2003-09-03 | — | — | EP | claimed |
| WO-2003057154-A2 | NAALADASE INHIBITORS FOR TREATING HUNTINGTON'S DISEASE | GUILDFORD PHARMACEUTICALS INC. (US) | 2003-07-17 | — | — | WO | claimed |
| US-20030083374-A1 | NAALADase inhibitors useful as pharmaceutical compounds and compositions | JACKSON PAUL F (US) | 2003-05-01 | — | — | US | claimed |
| US-20030013687-A1 | Pharmaceutical compositions and methods for treating anxiety, anxiety disorders and memory impairment using NAALADase inhibitors | SLUSHER BARBARA S (US) | 2003-01-16 | — | — | US | claimed |
| US-6458775-B1 | N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) INHIBITORS ENZYME ACTIVITY, PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH INHIBITORS, AND METHODS OF THEIR USE TO INHIBIT NAALADASE ENZYME ACTIVITY, THEREBY EFFECTING NEURONAL | GUILFORD PHARMACEUTICAL INC. | 2002-10-01 | — | — | US | claimed |
| US-6444657-B1 | 2-(PHOSPHONOMETHYL)PENTANEDIOIC ACID; 2-(2-SULFANYLETHYL) PENTANEDIOIC ACID; EPITHELIAL TISSUE SCARRING, COLLAGEN VASCULAR DISEASE, FIBROPROLIFERATION, CONNECTIVE TISSUE DISORDER, RESPIRATORY DISTRESS SYNDROME; TGF REGULATOR | GUILFORD PHARMACEUTICALS INC. | 2002-09-03 | — | — | US | claimed |
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | GUILFORD PHARMACEUTICALS INC., A DELAWARE CORPORATION | 2002-01-31 | — | — | US | claimed |
| WO-2001091738-A2 | NAALADASE INHIBITORS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | claimed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | claimed |
| US-6265609-B1 | INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY; IN DRUGS TO TREAT GLUTAMATE ABNORMALITIES; COMPULSIVE DISORDERS AND PROSTATE DISEASES, TO EFFECT NEURONAL ACTIVITIES | GUILFORD PHARMACEUTICALS INC. | 2001-07-24 | — | — | US | claimed |
| US-6228888-B1 | Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors | GUILFORD PHARMACEUTICALS INC. | 2001-05-08 | — | — | US | claimed |
| EP-1093453-A1 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARMACEUTICALS INC. (US) | 2001-04-25 | — | — | EP | claimed |
| WO-2000001668-A2 | NAALADASE INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-01-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013295-A1 | Naaladase inhibitors for treating amyotrophic lateral sclerosis | SMN1; SMN2, GAA, NAALAD2 | FOLH1 432/4885CYP1A2 3893/4885GRM3 182/4885 |
| US-20050080139-A1 | Naaladase inhibitors for treating huntington's disease | HTT, GAA, ADA | FOLH1 262/4885CYP1A2 3005/4885GRM3 832/4885 |
| US-20030013687-A1 | Pharmaceutical compositions and methods for treating anxiety, anxiety disorders and memory impairment using NAALADase inhibitors | GRIN1, GRIN2A, GRIN2B | FOLH1 224/4885CYP1A2 1289/4885GRM3 47/4885 |
| US-20030083374-A1 | NAALADase inhibitors useful as pharmaceutical compounds and compositions | NAALAD2, DNPEP, NAAA | FOLH1 22/4885CYP1A2 4318/4885GRM3 305/4885 |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | OPRD1, OPRK1, OPRM1 | FOLH1 254/4885CYP1A2 123/4885GRM3 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.